Stock 1541 IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Equities

1541

CNE100006624

Biotechnology & Medical Research

Delayed Hong Kong S.E.
Other stock markets
 06:18:48 31/05/2024 BST 		5-day change 1st Jan Change
14.32 HKD -1.38% Intraday chart for ImmuneOnco Biopharmaceuticals (Shanghai) Inc. -1.92% -52.11%
05-30 ImmuneOnco Completes Filing with China Regulator for Conversion of H Shares MT
05-28 ImmuneOnco Biopharmaceuticals Inc. Approves the Appointment of Guan Mei as Executive Director CI

Valuation

Fiscal Period: December 2023 2024 2025 2026
Capitalization 1 10,168 5,033 - -
Enterprise Value (EV) 1 9,872 4,539 4,487 4,652
P/E ratio - - - -
Yield - - - -
Capitalization / Revenue 26,343 x 8,552 x 6,755 x 5,974 x
EV / Revenue 25,574 x 7,713 x 6,021 x 5,522 x
EV / EBITDA -27.5 x -12 x -9.33 x -7.66 x
EV / FCF - - - -
FCF Yield - - - -
Price to Book 13.6 x 13.1 x -49.8 x -7.04 x
Nbr of stocks (in thousands) 374,158 374,158 - -
Reference price 2 27.18 13.45 13.45 13.45
Announcement Date 25/03/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2023 2024 2025 2026
Net sales 1 0.386 0.5885 0.7451 0.8424
EBITDA 1 -359.6 -379.4 -480.8 -607
EBIT 1 -372 -390.4 -490.4 -615.3
Operating Margin -96,368.39% -66,337.79% -65,820.02% -73,036.09%
Earnings before Tax (EBT) - - - -
Net income - - - -
Net margin - - - -
EPS - - - -
Free Cash Flow - - - -
FCF margin - - - -
FCF Conversion (EBITDA) - - - -
FCF Conversion (Net income) - - - -
Dividend per Share 2 - - - -
Announcement Date 25/03/24 - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2023 2024 2025 2026
Net Debt 1 - - - -
Net Cash position 1 297 494 547 382
Leverage (Debt/EBITDA) - - - -
Free Cash Flow - - - -
ROE (net income / shareholders' equity) - -67.2% -845% -
ROA (Net income/ Total Assets) - - - -
Assets - - - -
Book Value Per Share 2 2.000 1.030 -0.2700 -1.910
Cash Flow per Share - - - -
Capex - - - -
Capex / Sales - - - -
Announcement Date 25/03/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
13.45 CNY
Average target price
15.13 CNY
Spread / Average Target
+12.49%
Consensus

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC. Stock ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
-52.11% 695M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+8.92% 114B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.48% 105B
ARGENX SE Stock argenx SE
-1.83% 21.73B
BIONTECH SE Stock BioNTech SE
-6.45% 23.83B
GENMAB A/S Stock Genmab A/S
-10.39% 18.1B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.36% 16.34B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.45% 16.13B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.76% 13.75B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+28.94% 11.76B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 1541 Stock
  4. Financials ImmuneOnco Biopharmaceuticals (Shanghai) Inc.